BR9910860A - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
BR9910860A
BR9910860A BR9910860-7A BR9910860A BR9910860A BR 9910860 A BR9910860 A BR 9910860A BR 9910860 A BR9910860 A BR 9910860A BR 9910860 A BR9910860 A BR 9910860A
Authority
BR
Brazil
Prior art keywords
treatment
cyclosporins
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
BR9910860-7A
Other languages
Portuguese (pt)
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9910860A publication Critical patent/BR9910860A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"USO DE CICLOSPORINAS NO TRATAMENTO DE DOENçAS AUTO-IMUNES INFLAMATóRIAS"<D>. Ciclosporinas não-imunossupressivas que se ligam à ciclofilina, em particular [Melle]^ 4^-Ciclosporina, são úteis no tratamento e prevenção de doenças auto-imunes inflamatórias, tal como artrite reumatóide.Invention Patent: <B> "USE OF CYCLOSPORINS IN THE TREATMENT OF AUTO-IMMUNE INFLAMMATORY DISEASES" <D>. Non-immunosuppressive cyclosporins that bind cyclophilin, in particular [Melle] ^ 4 ^ -Cyclosporine, are useful in the treatment and prevention of inflammatory autoimmune diseases, such as rheumatoid arthritis.

BR9910860-7A 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases BR9910860A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (1)

Publication Number Publication Date
BR9910860A true BR9910860A (en) 2001-03-06

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910860-7A BR9910860A (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (en)
JP (2) JP4523154B2 (en)
KR (1) KR20010043969A (en)
CN (1) CN1304315A (en)
AU (1) AU750422B2 (en)
BR (1) BR9910860A (en)
CA (1) CA2333315A1 (en)
GB (1) GB9811854D0 (en)
HU (1) HUP0102142A3 (en)
ID (1) ID27576A (en)
IL (1) IL139589A0 (en)
NO (1) NO20006113L (en)
PL (1) PL344451A1 (en)
SK (1) SK18142000A3 (en)
TW (2) TWI250022B (en)
WO (1) WO1999062540A1 (en)
ZA (1) ZA200006464B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512436A (en) 1999-10-27 2003-04-02 アレクサンドラ ルーカス、 Compositions and methods for preventing and treating graft rejection
US7419670B2 (en) * 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007532507A (en) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト Use of cyclosporine for the treatment of cerebral ischemia and brain and spinal cord injury
MX2007000503A (en) 2004-07-14 2007-03-08 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv).
SG139750A1 (en) * 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
JP2008525458A (en) * 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト Flaviviridae treatment compounds
NZ555143A (en) * 2004-12-23 2009-12-24 Novartis Ag Compositions for HCV treatment
CN101242842A (en) 2005-06-17 2008-08-13 诺瓦提斯公司 Use of SANGLIFEHRIN in HCV
JP2007112775A (en) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine Use of cyclosporines in treatment of cytomegalovirus infection
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2280989B1 (en) 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CA2782898A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
CN104603146B (en) 2012-09-29 2018-01-02 诺华股份有限公司 Cyclic peptide compound and its purposes as medicine
WO2014063147A1 (en) * 2012-10-19 2014-04-24 Scynexis, Inc. New antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0484281T4 (en) * 1990-11-02 2001-02-05 Novartis Ag cyclosporines
AR006514A1 (en) * 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations

Also Published As

Publication number Publication date
EP1082130A1 (en) 2001-03-14
ZA200006464B (en) 2002-03-11
CA2333315A1 (en) 1999-12-09
JP2002516873A (en) 2002-06-11
TWI250022B (en) 2006-03-01
HUP0102142A3 (en) 2001-12-28
NO20006113L (en) 2001-01-25
NO20006113D0 (en) 2000-12-01
JP2010059177A (en) 2010-03-18
JP4523154B2 (en) 2010-08-11
IL139589A0 (en) 2002-02-10
PL344451A1 (en) 2001-11-05
AU4372499A (en) 1999-12-20
KR20010043969A (en) 2001-05-25
TW200522975A (en) 2005-07-16
SK18142000A3 (en) 2001-06-11
AU750422B2 (en) 2002-07-18
CN1304315A (en) 2001-07-18
WO1999062540A1 (en) 1999-12-09
GB9811854D0 (en) 1998-07-29
TWI250021B (en) 2006-03-01
HUP0102142A2 (en) 2001-11-28
ID27576A (en) 2001-04-12

Similar Documents

Publication Publication Date Title
BR9910860A (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
DK1091975T3 (en) New cyclosporine with improved activity profile
YU15299A (en) Pharmaceutical compositions
DE69731373D1 (en) CC CHEMOKINCEPTOR C-C CKR-5, THEIR DERIVATIVES AND USES
BR9710994A (en) Anticonvulsant derivatives useful in the treatment of obesity.
DE69936778D1 (en) ADENOASSOZED VIRUS VECTORS AND ITS USES
AU2003303458A1 (en) Ampholytic copolymer and use thereof
DE69905170T2 (en) THIAZOLOPYRIMIDINDERIVATE
DK1131065T3 (en) Diacyl dumarates for the treatment of autoimmune diseases
GB9717905D0 (en) Lipid-containing compositions and uses thereof
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
BR9402890A (en) Composition of siloxane-based lubricant in the hydrogen segregator.
TR200100462T2 (en) Muscarinic agonists and antagonists
EP1129106A4 (en) Cyclised conotoxin peptides
TR199802704T2 (en) Use of combinations containing Vx478, Zidovidin, FTC and/or 3TC in the treatment of HIV.
BR0009767A (en) Osteopontin-derived inhibitory and chemotactic agents and their uses
BR9909327A (en) Polymer compositions
EA200000875A1 (en) PROTEINS INTERACTING WITH CASPASE-8
ATE305517T1 (en) NEUROTRYPSIN
DE60134408D1 (en) FOR ACCRESSIVE HIV PROTEINS ENCODING DNA VACCINES
NO20005548D0 (en) Mykobakterieinhibitorer
IS4913A (en) Compositions containing VX 478, Zidovudine and / or 1592489 for use in the treatment of HIV
ES2122912A1 (en) Metalocarboxypeptidase inhibitors and derived molecules used as antitumor agents
ES2153760A1 (en) Inhibitor of metalocarboxypeptidases as fibrinolytic agent
TR200103662T2 (en) New calpains and their use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.